A mechanism is a chain—not the final result
A biological mechanism is a proposed account of how one event produces another. For an intervention, that account might begin with exposure, continue through binding or target engagement, alter one or more pathways, and eventually predict a measurable outcome.
Evidence for an early link does not automatically establish every later link. Showing that a compound binds a receptor answers a target question. Showing that signaling changes answers a pathway question. Neither result alone answers whether a meaningful outcome occurs in a person.
Each link needs its own support
A convincing mechanism depends on more than a biologically reasonable story. Researchers need evidence that the intervention reaches the relevant place at a relevant exposure, affects the proposed target, changes the downstream process, and connects that change with the outcome of interest.
The chain is only as useful as its uncertain links. A well-established receptor interaction can coexist with uncertainty about tissue exposure, downstream signaling, compensation, duration, or whether the measured change is large enough to matter.
Target engagement is important—but it is not the destination
Target engagement means that an intervention interacts with its intended biological target. A pharmacodynamic biomarker may then show that biological activity occurred. Both findings can provide valuable proof of mechanism or early proof of concept.
The FDA–NIH BEST resource explicitly separates biological activity from efficacy or disease outcome. A pathway can move in the predicted direction while the outcome remains unchanged, because the pathway was not the limiting factor, the change was too small or brief, or other processes offset it.
Biology contains side roads, feedback loops, and tradeoffs
Biological systems rarely behave like a single straight line. One target can participate in several pathways, pathways can converge on the same outcome, and feedback mechanisms can weaken, amplify, or reverse an expected effect.
An intervention may also produce effects outside the proposed chain. Those effects can add benefit, create harm, or cancel part of the predicted outcome. A mechanism focused on one desired pathway cannot establish the intervention’s full result or its overall balance of effects.
Context determines whether the chain travels
Mechanistic evidence is produced in a particular system: a purified protein, cultured cells, an animal model, healthy volunteers, or a defined patient group. Concentration, route, tissue, timing, genetics, disease state, and interacting pathways can all affect whether the same chain operates elsewhere.
This is why a mechanism observed in cells or animals cannot simply be carried into people unchanged. It may support plausibility and guide human testing, but the differences between the model and the target population remain part of the uncertainty.
Outcome research answers the question the mechanism predicts
Mechanistic and outcome evidence are partners, not rivals. Mechanistic evidence asks whether the proposed biological chain is credible and active. Outcome research asks whether the predicted result actually occurs under the studied conditions—and by how much.
When the two agree, the mechanism can strengthen interpretation and help explain the result. When they disagree, the outcome should not be dismissed to protect the story. The mismatch may reveal an incomplete mechanism, inadequate exposure, the wrong outcome measure, a context difference, or an effect too small to detect.
Key terms
- Biological mechanism
- A proposed sequence of biological events connecting a cause or intervention with an effect.
- Target engagement
- Evidence that an intervention reached and interacted with its intended biological target.
- Pathway
- A connected set of biological signals or processes through which an effect may develop.
- Pharmacodynamic biomarker
- A measurement showing biological activity after an exposure, without necessarily establishing efficacy or a disease outcome.
- Clinical outcome
- A result describing how a person feels, functions, or survives.
- Surrogate endpoint
- A measurement used in place of a direct clinical outcome because evidence supports—or is expected to support—its ability to predict that outcome in a defined context.
Relay diagram
A plausible chain still needs an outcome test
What this can—and cannot—tell us
What it can tell us
- Why an outcome may be biologically plausible.
- Whether an intervention reaches a target or changes a proposed pathway under the tested conditions.
- Which biomarkers, outcomes, time points, and possible harms researchers may need to measure.
- How several findings may fit together—or why results might differ across contexts.
- Which parts of a causal explanation are well supported and which remain hypothetical.
What it cannot establish alone
- That the predicted final outcome occurs in people.
- How large, durable, or meaningful that outcome will be.
- That the same chain operates across every tissue, population, exposure, route, or timeframe.
- That a biomarker change reliably predicts a clinical outcome unless that relationship has been supported in the relevant context.
- That benefits outweigh harms or that no important off-target effects exist.
Go deeperOptional · about 2 minutes
Mechanism of action and causal mechanism are related—but not identical
Mechanism of action usually describes how an intervention produces a pharmacologic effect, such as binding a receptor or inhibiting an enzyme. A complete causal explanation for a person-relevant outcome is broader: it must also connect exposure, tissue effects, downstream biology, competing causes, and the final measured result.
Knowing the mechanism of action can therefore establish an important part of the chain without establishing the entire pathway from intervention to outcome.
Why a biomarker needs more than a persuasive mechanism
A pharmacodynamic biomarker may show that a compound is biologically active. To use a biomarker as a validated surrogate for a clinical benefit, the FDA–NIH BEST framework generally requires both a clear mechanistic rationale and clinical data showing that changes in the surrogate predict the clinical outcome in a defined context.
This distinction matters because a biomarker can sit on the proposed pathway yet fail to capture every way an intervention affects the final outcome. Clinical validation tests whether the prediction actually holds.
Regulatory evidence is context-specific
A 2026 FDA revised draft guidance allows mechanistic evidence to serve as confirmatory evidence in some narrow situations—especially when disease biology and the intervention’s action are unusually well understood. A 2026 draft framework also addresses individualized therapies for ultra-rare genetic conditions with known biological causes.
These frameworks do not turn plausibility into universal proof. They combine mechanism with other evidence, define a specific context of use, and may require continued outcome and safety follow-up. A regulatory decision and a claim that an outcome has been directly demonstrated are not the same statement.
The takeaway
If you only remember one thing from this guide:
A biological explanation can make an outcome plausible. It cannot establish that the outcome occurs in people.
Sources and support7 sources
- Evidence-based mechanistic reasoning Howick, Glasziou, and Aronson
Defines mechanistic reasoning as an inference from mechanisms to a claim that an intervention produced a patient-relevant outcome and examines how that inference should be appraised.
- Problems with using mechanisms to solve the problem of extrapolation Howick, Glasziou, and Aronson
Explains how incomplete knowledge, laboratory context, paradoxical behavior, and extrapolation can limit mechanism-based predictions.
- BEST Resource: Response Biomarker FDA–NIH Biomarker Working Group
Distinguishes pharmacodynamic biological activity and target engagement from conclusions about efficacy or disease outcome.
- Surrogate Endpoint Resources for Drug and Biologic Development U.S. Food and Drug Administration
Explains that surrogate endpoints predict rather than directly measure clinical benefit and require context-specific supporting evidence.
- BEST Resource: Validated Surrogate Endpoint FDA–NIH Biomarker Working Group
States that validation generally joins a clear mechanistic rationale with clinical data showing prediction of a specific benefit.
- Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products U.S. Food and Drug Administration
The June 2026 revised draft describes narrow circumstances in which mechanistic evidence may serve as confirmatory evidence alongside one adequate and well-controlled trial.
- Considerations for the Use of the Plausible Mechanism Framework for Individualized Therapies U.S. Food and Drug Administration
Provides a 2026 draft framework for combining mechanistic, biomarker, nonclinical, outcome, and safety evidence in ultra-rare genetic conditions.